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Introduction
Transcription factors, RNA binding proteins, and 
microRNAs (miRNAs) are among the factors that must 
act coordinately to control gene expression networks 
important for cellular function [1]. Following transcrip-
tion, mRNAs are subject to the processes of splicing, 
nuclear export, traﬃ   cking, and polyadenylation, followed 
by translation initiation and elongation. Each of these 
processes represents a point at which expression can be 
regulated, allowing for ﬁ  ne-tuning in response to chang  ing 
environmental conditions. miRNAs are short (approxi-
mately 21-nucleotide) non-coding RNAs that regulate 
trans  cript localization, polyadenylation, and translation. 
miRNAs are direct negative regulators of gene expression 
that bind to speciﬁ  c sequences within a target mRNA [2,3].
miRNAs were discovered as a result of studies aimed at 
identifying genes that mediate developmental transitions 
in Caenorhabditis elegans [4,5]. Recent years have seen 
signiﬁ  cant advances in the miRNA ﬁ  eld, including the 
characterization of the miRNA biogenesis pathway, 
identi ﬁ  cation of the mechanisms by which miRNAs regu-
late gene expression, and an appreciation of how families 
of miRNAs can regulate cellular processes and contribute 
to disease phenotypes.
Th  e goal of this review is to highlight our current 
under  standing of miRNA biogenesis and mechanisms of 
action, and to summarize recent studies on the role of 
miRNAs in bone remodeling.
miRNA biogenesis
Th   e miRNA biogenesis pathway has several steps: trans-
cription, pri-miRNA processing, transport to the cyto-
plasm, precursor miRNA (pre-miRNA) processing, 
strand selection, transcript targeting, and transcript fate 
(Figure 1). Th  is rigorous, multistep processing pathway 
helps ensure that only RNAs with the correct structures 
and sequences are able to regulate gene expression.
miRNA genes are found on every chromosome in 
humans, except for the Y chromosome. Like the promo-
ters of protein-coding genes, miRNA promoters are 
regulated by epigenetics and by transcription factors. 
miRNA genes are transcribed by RNA polymerase II or 
III, from independent miRNA genes, or from the introns 
of protein-coding or non-protein-coding genes [6,7] 
(Figure  2). Th  e initial product of miRNA gene trans-
cription is the primary transcript (pri-miRNA), which 
may be several thousand nucleotides long. Multiple 
miRNAs may be co-transcribed in a single pri-miRNA. 
Th   e entire pri-miRNA is capped and polyadenylated, like 
mRNA transcripts. Tandem transcription of several 
miRNAs, possibly along with protein-coding genes, 
allows the genes to be expressed together. Th  ese co-
expressed genes may interact within the same pathway or 
through crosstalk between pathways. Th  e co-expression 
of miRNA and protein-coding genes may also function to 
ensure negative feedback on the protein-coding gene to 
prevent its over-expression [8].
In mammals, the pri-miRNA is processed within the 
nucleus by the Drosha-DiGeorge syndrome critical 
region gene 8 (DGCR8) complex (Figure 1, in nucleus). 
Drosha is an RNase III-type endonuclease, and DGCR8 is 
thought to recruit and bind the transcript [9]. Th  e 
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the pri-miRNA form an imperfect stem that is recognized 
by DGCR8, which allows Drosha to cleave approximately 
11 bp away [9,10]. Pri-miRNAs are cleaved into precursor 
miRNAs (pre-miRNA), which are approximately 60- to 
100-nucleotide hairpins. Th  e pre-miRNA is then trans-
ported from the nucleus into the cytoplasm by Exportin5 
and Ran-GTP [11]. Exempted from this processing 
pathway are short introns containing miRNA precursors, 
called ‘mirtrons’ (Figure 2). Spliced and debranched 
mirtrons are able to bypass processing by Drosha, and 
access the canonical miRNA processing pathway follow-
ing nuclear export [12].
Pre-miRNAs are further processed by the Dicer-TAR 
RNA binding protein (TRBP) complex [13] (Figure 1, in 
cytoplasm). Dicer is another RNase III-type endo-
nuclease, and TRBP is thought to recruit and bind the 
pre-miRNA, and to stabilize the Dicer-RNA interaction. 
Th  ere are several requirements for duplex recognition 
and cleavage by Dicer [14]. For example, only miRNA 
duplexes with central mismatches will form an eﬃ   cient 
complex with Dicer/Ago1 (Argonaute). Mismatches in 
the seed region or 3’ end promote unwinding of the 
duplex, whereas the terminal loop may promote enzyme 
turnover [14,15]. Dicer cleavage yields an approximately 
21-nucleotide miRNA duplex, which is incorporated into 
Figure 1. MicroRNA biogenesis pathway. miRNAs are transcribed by RNA polymerase (Pol) II or III into primary (pri)-miRNAs, which are processed 
by Drosha/DGCR8 (DiGeorge syndrome critical region gene 8) into precursor (pre)-miRNAs. The mature miRNA strand is highlighted in red. The pre-
miRNA is transported from the nucleus into the cytoplasm by Exportin 5, where it is then processed by Dicer/TRBP (Dicer-TAR RNA binding protein) 
into a miRNA duplex. The duplex is unwound by a helicase and the mature strand (red) is incorporated into the RNA-induced silencing complex 
(RISC). Depending on miRNA complementarity to a target mRNA, the RISC mediates down-regulation of gene expression by either translational 
repression or mRNA degradation. Ago, Argonaute; PACT, protein activator of PKR; P-body, processing body.
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includes Dicer, TRBP, PACT (protein activator of PKR), 
and one of four Ago proteins [16]. Th   e miRNA duplex is 
unwound by helicases into two single strands, the mature 
guide strand (miRNA; red strand in Figure 1) and the 
complementary passenger strand (miRNA*) [14]. Guide 
strand selection is dependent on the ﬁ  rst 5’ nucleotides 
and which Ago protein is present in the RISC [17].
Th   e miRNA* is typically degraded by the RISC, although 
some miRNAs* are thought to negatively regulate gene 
expression, like a mature miRNA. It is not known why 
some miRNAs* are functional. One hypothesis is that the 
strands could be used diﬀ   erently in response to extra-
cellular or intracellular cues, to regulate a more diverse set 
of protein-coding genes as needed, or strand selection 
could be tissue speciﬁ  c [18]. Strand selection also limits 
regulation by miRNAs* generated from highly expressed 
precursors.
While the mechanisms regulating miRNA biogenesis 
have been well studied, the regulation of miRNA stability, 
particularly in vertebrates, is not well understood. It is 
known that mature miRNA abundance is sensitive to Ago 
protein levels, suggesting that association with Ago can 
protect miRNAs from degradation [19]. Although most 
miRNAs appear to be stable, they do possess diﬀ  erential 
stability. One miRNA, miR-122, was recently shown to be 
stabilized by the addition of a single adenosine to its 3’ 
end through the activity of the cytoplasmic poly(A) 
polymerase GLD-2. In contrast, uracils at positions 9 to 
11 are important for the short half-life of miR-29b [15]. 
miR-382 also has a short half-life, due to sequence 
elements in the 3’ end of the miRNA. Th   e exosome 3’-5’ 
exonuclease complex was shown to be important for 
miR-382 decay [20]. Discovery and characterization of 
cis- and trans-acting factors regulating miRNA stability is 
a topic of intense study.
miRNA functions
Once the RISC contains the guide strand, it delivers the 
miRNA to the target mRNA, where base pairing occurs. 
Most miRNA binding sites lie within the 3’ UTR, 
although there are some reports of miRNAs binding in 
the 5’ UTR and coding region of mRNAs [21,22]. Th  ere 
appears to be a biological basis for the preferential inter-
action of miRNAs with the 3’ UTR. Data suggest that 
miRNA binding sites within the coding region of a trans-
cript are less eﬀ  ective at mediating translational repres-
sion. Th  is is likely due to the ability of ribosomal com-
plexes to override and inhibit the interaction of the 
miRNA-RISC with the potential binding site(s) [23]. 
Similarly, relatively few functional miRNA binding sites 
are located in the 5’ UTR of a transcript. Th  e scanning 
activity of the ribosome may impair the interaction of the 
miRNA-RISC with the 5’ UTR, suggesting there would 
be ineﬃ   cient inhibition of gene expression. Although the 
general location of a miRNA binding site within the 
transcript helps deﬁ  ne the degree of repression mediated 
by miRNAs, other factors contribute to eﬃ   cacy. Th  ese 
factors include the sequence context of the miRNA 
binding site, the number of target sites within the mRNA, 
the local RNA structure, and distance between target 
sites [24-27].
Th   e degree of base pairing between the miRNA and its 
target determines the fate of the transcript. Of particular 
importance is the interaction between the ‘seed’ region of 
the miRNA (nucleotides 2 to 8) and the 3’ end of the 
trans  cript’s miRNA binding site. Th   e seed region nucleates 
miRNA binding. If there is perfect binding between the 
miRNA and target, the mRNA target is cleaved by the 
endonuclease Ago2, possibly in RNA processing bodies 
(P-bodies) [28,29]. However, most metazoan miRNAs 
bind imperfectly to their targets, triggering translational 
repression. In such cases of imperfect miRNA-mRNA 
Figure 2. Genomic orgranization of microRNA genes. miRNA genes can be intergenic (alone or clustered), in the intron of non-coding RNA or 
protein-coding genes (alone or clustered), or can be mirtrons (part of a short intron of another gene).
Kapinas and Delany Arthritis Research & Therapy 2011, 13:220 
http://arthritis-research.com/content/13/3/220
Page 3 of 11binding, there is frequently a bulge between the miRNA 
and its target, between the 9th and the 11th nucleotide of 
the miRNA, which induces translational suppression [30].
For a majority of mRNAs, translation initiation occurs 
when the 5’-cap m7GpppN is recognized by eIF4E, a 
component of the eukaryotic translation initiation factor 
eIF. Th  is complex also includes eIF4G, which interacts 
with eIF3, to recruit the 40S ribosomal subunit, and with 
polyadenylate-binding protein 1 (PABP1). Th  e  interaction 
of eIF4G with both eIF4E and PABP1 physically brings 
the 5’ and 3’ ends of the mRNA close together, stimulating 
translation initiation by increasing aﬃ   nity of eIF4E for 
the 5’-cap. Trans-acting factors that bind the 3’ UTR 
inhibit translation by recruiting proteins that block the 
eIF4E-eIF4G interaction or that bind to the 5’-cap, 
preventing assembly of the 40S ribosome initiation com-
plex [31]. Several studies have shown this to be the case for 
components of the RISC, speciﬁ  cally Ago proteins [32,33]. 
Th  e central domain of the Ago protein family has some 
sequence homology to the eIF4E cap-binding domain. 
Mutation of these residues in Ago proteins abolishes 
translational repression of m7G mRNAs, suggest  ing that 
Agos can compete with eIF4E to inhibit translation [34].
miRNAs can also repress translation at post-initiation 
steps. miRNA-RISC can bind to actively translating 
mRNAs, reducing translational elongation and/or enhan-
cing termination, concomitant with a reduction in ribo-
somal initiation and nascent peptide destabilization. As a 
component of the RISC, Ago proteins 1, 3, and 4 are 
thought to mediate post-initiation inhibition [35,36].
Initial studies of miRNA targets suggested that only the 
protein levels of regulated targets were decreased, where-
as the levels of target mRNAs themselves were not 
aﬀ  ected. However, altering miRNA expression in cells or 
tissues can cause signiﬁ   cant changes in target mRNA 
levels, suggesting that miRNAs can induce mRNA 
destabilization [29,37]. In eukaryotes, mRNA degradation 
can occur when there is a shortening of the poly(A) tail. 
As part of the RISC, Ago proteins 1, 3, and 4 are thought 
to repress translation by promoting poly(A) tail-mediated 
degradation [38]. One study demonstrated that miRNA-
mediated deadenylation of maternal mRNAs is necessary 
during zebraﬁ  sh embryogenesis [37].
Further, miRNAs function in P-bodies by sequestering 
target transcripts for storage, decapping, deadenylation, 
and degradation [28]. Interestingly, P-bodies may also act 
as a temporary storage space for translationally repressed 
mRNAs. Since most P-body components are also found 
dispersed in the cytosol, it is likely that repression by 
these proteins is initiated in the cytosol, and the 
repressed mRNAs then aggregate to form the P-body. 
Stress granules are another type of body containing 
repressed mRNAs, and they accumulate in response to 
stress conditions or general inhibition of translation [39].
Bone remodeling
Th  e skeleton is continuously remodeled throughout the 
lifetime of an individual, and this remodeling is a dynamic 
process by which bone resorption is coupled to bone 
formation, to replace damaged bone or to respond to 
metabolic needs [40]. To provide some context in which to 
appreciate the function of miRNAs in the skeleton, we will 
brieﬂ   y consider the steps of bone remodeling and the 
signals important for osteoclast and osteoblast maturation.
Bone remodeling, or turnover, is mediated by the 
delicate balance of osteoblast and osteoclast numbers 
and activities (Figure 3). Osteoclasts resorb bone, where-
as osteoblasts synthesize new bone. Th  e release of 
cytokines at the site of remodeling recruits osteoclasts to 
the bone surface. Th   e osteoclasts form a ruﬄ   ed boarder 
that allows their tight adherence to the bone surface. Th  e 
space between the osteoclast and the underlying bone 
becomes an isolated microenvironment into which the 
osteoclast’s proton pump releases ions that generate an 
acidic environment, dissolving the mineralized compo-
nent of the bone matrix. Th  e organic matrix becomes 
exposed and is subsequently degraded by cathepsin K 
[41]. Th   e reversal phase of bone remodeling begins with 
mononuclear cells preparing the bone surface for new 
osteoblasts and providing signals to recruit them. Early 
osteoblasts proliferate and secrete an extracellular matrix 
abundant in type I collagen. As the osteoblasts continue 
to diﬀ  erentiate, the matrix matures and is mineralized. 
Once the bone surface is restored, mature osteoblasts can 
undergo apoptosis or terminally diﬀ  erentiate into either 
bone surface lining cells or osteocytes, which are 
embedded in the calciﬁ  ed matrix and are responsive to 
mechanical stresses [42].
Diﬀ   erentiation of osteoclasts and osteoblasts from 
multipotent precursors is a critical component of bone 
turnover. Osteoclasts are derived from the monocyte/
macrophage lineage. Diﬀ   erentiation into osteoclasts is 
dependent on multiple extracellular signaling molecules, 
including macrophage colony-stimulating factor (MCSF), 
receptor activator for nuclear factor κB ligand (RANKL), 
tumor necrosis factor, interferon gamma, and inter-
leukins [41].
Osteoblasts are derived from mesenchymal stem cells 
(MSCs), which can diﬀ  erentiate into osteoblasts, adipo-
cytes, chondrocytes, or myocytes, depending on the 
activation or inhibition of speciﬁ   c signaling pathways 
[43]. Some of the most important signaling molecules 
regu lat ing  osteoblastic  diﬀ  erentiation  include  bone 
morpho  genetic proteins (BMPs), transforming growth 
factor (TGF)-β, WNT, Hedgehog, parathyroid hormone, 
insulin-like growth factor-1, ﬁ   broblast growth factors, 
and Notch.
Misregulation of osteoclastic or osteoblastic diﬀ  eren-
tia  tion could result in dysregulation of bone balance and 
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miRNAs have been shown to regulate osteoblast and 
osteoclast diﬀ   erentiation and function. Th  e following 
section will summarize the known roles of miRNAs in 
osteoblast and osteoclast biology.
miRNAs in osteoblasts
Cell type-speciﬁ  c deletion of Dicer in committed osteo-
progenitors results in embryonic lethality at embryonic 
day (E)14.5 [44]. Th   e mutant embryos display a deformed 
cartilaginous skeleton, and a lack of bone formation. Th  is 
study used the rat 2.3-kb Col1a1 promoter driven-Cre 
construct to delete the ﬂ  oxed Dicer alleles, and this Cre 
construct is transiently expressed during embryonic 
develop  ment, likely causing the embryonic lethality. 
Th  ese data reinforce the concept that Dicer-mediated 
miRNA processing is critical for osteogenesis.
Targeted deletion of Dicer in mature osteoblasts, using 
an osteocalcin-Cre construct, led initially to delayed 
perinatal bone formation, with a subsequent increase in 
postnatal bone acquisition [44]. In these mice, signiﬁ  cant 
increases in cortical and trabecular bone volume were 
evident at 4 months of age, and persisted to 8 months. 
Long bone from mice lacking Dicer expression in mature 
osteoblasts had increased levels of mRNA for type I 
collagens, RANKL, and tartrate-resistant acid phospha-
tase (TRAP). Although data on osteoblast and osteoclast 
number were not reported, these results suggest 
increased bone remodeling in the mutant mice. In con-
trast, another group deleted Dicer in mature osteo  blasts 
using a mouse 2.3-kb Col1 promoter driven-Cre con-
struct, and reported no eﬀ  ect on bone phenotype [45]. 
Comparing these two studies, it is likely that diﬀ  erences 
in the degree of Cre-mediated recombination and cell 
type speciﬁ  city had an impact on the resulting mouse 
phenotypes. Nevertheless, these data suggest that Dicer 
activity is important for controlling both early and late 
bone cell diﬀ  erentiation programs.
In vitro knockdown of Dicer or Drosha in human MSCs 
inhibited osteogenic diﬀ  erentiation,  conﬁ  rming  similar 
eﬀ   ects in human cells [46]. Indeed, since Dicer is 
important for the processing of many miRNAs, dramatic 
eﬀ  ects on cell diﬀ  erentiation with Dicer ablation are not 
unexpected. However, Dicer-independent mechanisms 
for miRNA maturation have recently been described [47]. 
It will be interesting to consider how these mechanisms 
may impact skeletal phenotype and to identify which 
miRNAs are regulated by these alternative pathways.
Th   e BMP signaling pathway plays a prominent role in 
promoting osteoblast diﬀ  erentiation and bone formation 
[48]. Several studies have focused on miRNAs modulated 
by BMP signaling as a means to understand the role of 
miRNAs in osteoblasts. From these studies, it is clear that 
a panel of BMP-regulated miRNAs is important for the 
regulation of osteoblast diﬀ   erentiation. Since some 
miRNAs can be co-expressed and/or co-regulated, it is 
possible that families of miRNAs may promote one 
pheno  type at the expense of another. Th   is appears to be 
the case for miR-133 and miR-135, which are down-
regulated during BMP-2-induced osteoblastic 
diﬀ  erentiation of C2C12 premyogenic cells, but are up-
regulated in these cells during myoblastic diﬀ  erentiation 
[49]. Over-expression of miR-133 or miR-135 blocked the 
BMP-mediated induction of osteoblastic markers, such 
Figure 3. Bone remodeling. Bone remodeling begins when osteoclasts resorb bone mineral and matrix. Mononuclear cells prepare the resorbed 
surface for osteoblasts, which generate newly synthesized matrix as they diff  erentiate. Matrix mineralization and the diff  erentiation of some 
osteoblasts into osteocytes completes the remodeling cycle.
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Further studies demonstrated that Runx2 is a target for 
miR-133, and Smad5 is a target for miR-135. Runx2 is a 
transcription factor essential for osteoblast diﬀ  eren-
tiation, whereas Smad5 is an intracellular Runx2 co-
receptor [50,51]. Th  e concomitant down-regulation of 
these two miRNAs by BMP-2 likely plays an important 
role in the up-regulation of Runx2 and Smad5 during 
osteogenic diﬀ  erentiation.
Similarly, miR-206 is decreased in response to BMP-2 
in C2C12 cells and during diﬀ   erentiation of primary 
murine osteoblasts [52]. Over-expression of miR-206 
inhibits ALP activity, and Connexin 43 (Cx43) was shown 
to be a target of miR-206. Cx43 is a gap junction protein 
necessary for osteoblast diﬀ  erentiation and function [53]. 
In vivo, miR-206 is highly expressed in muscle and 
perichondrial osteoblasts at E14.5, is moderately ex-
pressed in bone collar cells at E16.5, and is undetectable 
in bone at E18.5. Transgenic mice expressing miR-206 in 
mature osteoblasts display a low bone mass phenotype, 
particularly evident in the trabecular compartment. Bone 
formation rate was decreased in the transgenic mice, 
suggesting a defect in osteoblast function, whereas the 
osteo  clast surface was unchanged. Th  ese data conﬁ  rm 
miR-206 as a negative regulator of osteoblast function.
Th  e sequences of mature miR-141 and miR-200a are 
very similar, and these two miRNAs are decreased in 
BMP-2-treated MC3T3-E1 osteoblastic cells. miR-141 
and -200a appear to be negative regulators of osteoblast 
diﬀ  eren  tiation, since their over-expression inhibits this 
process. Dlx5 (Distal-less homeobox 5) is a master 
osteogenic transcription factor, and the 3’ UTR for Dlx5 
has a potential binding site for miR-141 or -200a [54]. In 
cells over expressing miR-141 or -200a, Dlx5 protein 
levels were decreased. Since Dlx5 activates the trans  crip-
tion of osterix, a transcription factor crucial for osteo-
blast diﬀ   er  entiation, it is possible that the BMP-2-
induced repres  sion of miR-141 and -200a expression may 
indirectly augment the transcription of osterix, to 
promote osteo  blastogenesis [55].
BMP-2 was also shown to decrease the expression of 
miR-208 [56]. Over-expression of miR-208 antagonized 
the BMP-2-mediated osteoblastic diﬀ  erentiation  of 
MC3T3-E1 cells and primary mouse osteoblasts. Th  e 
osteogenic transcription factor Ets1 was shown to be a 
target of miR-208. Ets1 stimulates the transcription of 
osteopontin and Runx2, and this was inhibited by 
miR-208 over-expression [56,57]. Th   us, BMP-2 decreases 
miR-208 expression, allowing up-regulation of Ets1 and 
promoting osteoblastic diﬀ  erentiation.
In ST2 mouse mesenchymal cells, miR-125b expression 
is decreased after a 6-day treatment with BMP-4. miR-
125b has a negative eﬀ  ect on osteoblastic diﬀ  erentiation, 
as over-expression of miR-125b decreased ALP activity 
and knockdown of miR-125b increased ALP. Potential 
targets for miR-125b in osteoblasts have not been 
validated; however, miR-125b may play a role in regulat-
ing cell proliferation [58]. In contrast, miR-210 was found 
to be increased during BMP-4-induced osteoblastic 
diﬀ  erentiation of ST2 cells [59]. miR-210 plays a positive 
role in osteoblast diﬀ  erentiation. Transcripts for ALP and 
osterix were increased in ST2 cells over-expressing 
miR-210. Activin A receptor type 1B (AcvR1b) was 
identiﬁ  ed as a target of miR-210. AcvR1b is essential for 
activin signaling, which may play a role in repressing 
osteoblastic diﬀ  erentiation [60].
Commitment of mesenchymal cells to a particular 
lineage depends on intracellular and extracellular cues to 
guide diﬀ   erentiation. miR-204 is induced during the 
adipo genic  diﬀ   erentiation of murine C3H10T1/2 cells 
and human MSCs. Concomitantly, Runx2 is decreased. 
Runx2 is a target for miR-204. Over-expression of miR-204 
negatively regulates Runx2 expression, inhibits osteoblast 
diﬀ   erentiation, and promotes adipocyte diﬀ  erentiation 
[61]. Runx2 can also be negatively regulated by some 
members of the miR-23a/27a/24-2 cluster in murine 
osteoblasts [62]. Th   e cluster is up-regulated during diﬀ  er-
en  tiation of rat osteoblasts, but only miR-23 appears to 
directly target the Runx2 3’ UTR.
During terminal osteoblastic diﬀ  erentiation of human 
adipocyte-derived stem cells, miR-26a expression is 
increased. Further, as miR-26a increases, SMAD1 levels 
decrease. SMAD1 was shown to be a target for miR-26a, 
and knockdown of miR-26a increased the expression of 
osteoblast maker genes, including those encoding COL1A1, 
osteopontin, and osteocalcin [63]. SMAD1 is a critical 
downstream mediator of BMP signaling, and increased 
expression of SMAD1 augments osteoblasto  genesis.
miR-199a and -346 are up-regulated during osteoblastic 
or adipogenic diﬀ  erentiation of human MSCs [46]. Th  ese 
miRNAs negatively regulate leukemia inhibitory factor 
(LIF), which is a marker for human MSC multipotency, 
and is associated with the uncommitted state of embry-
onic and adult stem cells [64]. Indeed, expression of LIF 
is decreased as stem cell plasticity is decreased. Th  e 
inhibition of LIF by miR-199a and -346 in human MSCs 
likely contributes to the induction of diﬀ  erentiation.
Th  e miR-29 family is one of the best characterized 
miRNA families with regard to osteoblast function, and 
these miRNAs are important positive regulators of 
osteoblast diﬀ  erentiation.  Th  e expression of miR-29 
family members is low during the early, matrix deposition 
phases of osteoblastogenesis. A low level of miR-29 
expression is important at this time since miR-29 targets 
bone matrix RNAs, including COL1A1,  COL3A1, and 
osteonectin (ON)/SPARC (secreted protein acidic and 
rich in cysteine) [65,66]. Th   e co-regulation of osteonectin 
and ﬁ   brillar collagens is not unexpected, since 
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ﬁ  bril formation [67].
Later, the expression of miR-29 is increased as the 
matrix matures and the osteoblast achieves terminal 
maturation. Th   is increase in miR-29 likely plays a role in 
the time-dependent suppression of collagen synthesis, 
which may be necessary to prevent ﬁ  brosis, and to allow 
for subsequent mineral deposition and proper ﬁ  bril 
alignment, both of which are necessary for normal bone 
turnover [68,69]. Over-expression of miR-29 family 
members promotes osteoblastic diﬀ  erentiation, whereas 
knockdown of miR-29 decreases diﬀ  erentiation markers. 
It is interesting to note that other validated targets for 
miR-29, important in osteoblast function, include several 
proteins that are inhibitors of osteoblast diﬀ  erentiation, 
such as histone deacetylase (HDAC)4, TGFβ3, AcvR2A, 
CTNNBIP1 (catenin beta interacting protein I), and 
DUSP2 (dual speciﬁ  c phosphatase 2) [70].
It was recently reported that canonical Wnt signaling, a 
critical positive regulator of osteoblast diﬀ  erentiation, 
rapidly induces the expression of miR-29a and -29c [65]. 
Since activation of canonical Wnt signaling tends to 
increase during osteoblast diﬀ  erentiation, it is possible 
that Wnt signaling plays a role in the increased expression 
of miR-29 observed during osteoblast diﬀ  erentiation [71]. 
Further, miR-29a modulates canonical Wnt signaling in a 
positive feedback loop, to promote human osteoblast 
diﬀ  erentiation [72]. In human osteoblasts, transcription 
of miR-29a is induced by canonical Wnt signaling, and 
two T-cell factor/lymphoid enhancer factor (TCF/LEF) 
binding sites in the miR-29a promoter region are 
necessary for this induction. miR-29a was also found to 
target three inhibitors of Wnt signaling, Dkk1 (dikkopf-1), 
Kremen2 (kringle domain-containing transmembrane 
protein), and sFRP2 (secreted frizzled related protein 2). 
Th   us, the induction of miR-29a transcription, in response 
to canonical Wnt signaling, results in decreased Dkk1, 
Kremen2, and sFRP2 levels, which potentiates Wnt 
signal ing.  Th   is loop provides an additional mechanism by 
which miR-29 can promote human osteoblast diﬀ  eren-
tiation, and a mechanism for ﬁ  ne tuning the expression 
of speciﬁ   c components in the Wnt signaling pathway 
[71,72].
A similar study demonstrated that miR-27, which is 
increased during osteoblast diﬀ  erentiation,  positively 
regu  lates this process by targeting adenomatous poly-
posis coli (APC) [73]. In the absence of canonical Wnt 
signaling, APC is part of an inhibitor complex that binds 
β-catenin, preventing β-catenin translocation to the 
nucleus. Th   is study suggests miR-27 promotes osteoblast 
diﬀ  erentiation by down-regulating APC, thus allowing 
for Wnt signaling. Indeed, over-expression of miR-27 
increased ALP and osteocalcin, whereas its inhibition 
decreased these markers.
In the ﬁ  rst study assessing miRNAs and osteoporosis in 
humans, an inactivating mutation in miR-2861 was found 
to be associated with decreased serum markers of osteo-
blast activity in a kindred of osteoporosis patients [74]. 
Interestingly, miR-2861 appears to be a bone-enriched 
miRNA. It is highly expressed in osteoblasts, with a lower 
level of expression in liver. Knockdown of miR-2861 in 
mice resulted in decreased bone volume, bone formation 
rate and osteoblast surface. Conversely, increased expres-
sion of this miRNA in vitro augmented osteoblast 
diﬀ  erentiation. miR-2861 was shown to target the protein 
coding region of HDAC5. HDAC5 mediates deacetylation 
of Runx2 and deacetylated Runx2 undergoes Smurf1-
mediated degradation [75]. Th   erefore, HDAC5 inhibition 
by miR-2861 likely increases the abundance of acetylated 
Runx2, allowing for augmentation of osteoblast diﬀ  eren-
tiation. Th  is key study demonstrates the importance of 
miRNA genes and their contribution to human disease 
phenotypes.
Transcribed in the same pri-miRNA as miR-2861 is 
another novel miRNA, miR-3960. Th  ese miRNAs likely 
work in concert, promoting osteoblastic diﬀ  erentiation 
by indirectly up-regulating Runx2 [76]. When miR-3960 
is over-expressed, ALP, osteocalcin, and Runx2 are 
increased. Conversely, these diﬀ  erentiation markers are 
decreased when miR-3960 is inhibited. miR-3960 was 
found to directly target Hoxa2, a negative regulator of 
Runx2. Th   us, the down-regulation of Hoxa2 by miR-3960 
results in increased Runx2 expression. Further, Runx2 
can bind the miR-3960 promoter, suggesting regulation 
of this miRNA cluster.
Overall, it is clear that miRNAs play an important role 
in osteoblast function and diﬀ  erentiation (summarized in 
Table 1). Future work, deﬁ  ning the function of particular 
miRNAs in osteoblast commitment and diﬀ  erentiation, 
could allow for the assembly of a panel of miRNAs that 
could be used as diﬀ  erentiation markers, similar to the 
panel of markers presently used to annotate the 
progression of diﬀ   erentiation, such as Runx2, ALP, 
osteocalcin, and osterix.
miRNAs in osteoclasts
Studies addressing the role of miRNAs in osteo  clasto-
genesis are relatively limited. However, cell-type-speciﬁ  c 
deletion of Dicer at diﬀ   erent stages in the osteoclast 
lineage highlight the general importance of miRNAs in 
osteoclast function. For example, deletion of Dicer in 
mature osteoclasts, using a cathepsin K promoter driven-
Cre transgene in mice bearing ﬂ   oxed Dicer alleles, 
resulted in increased bone mass in the trabecular 
compart  ment, due to a decrease in osteoclast number 
and surface [45]. Osteoclastogenesis in vitro was sup-
pressed, suggesting a cell autonomous phenomenon. 
Interestingly, deletion of Dicer in mature osteoclasts also 
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Page 7 of 11resulted in decreased bone formation rate, indicating an 
overall decrease in bone remodeling. Th  ese authors 
reported that miRNA expression microarray analysis 
showed little change in the miRNA proﬁ   le in bone 
marrow macrophages (BMMs) treated for 24 hours with 
MCSF/RANKL to induce osteoclastogenesis. In this 
study, expression of miR-302c was stimulated to the 
greatest extent (approximately 1.8-fold), and this miRNA 
has been implicated in stem cell pluripotency [77].
Similar results were obtained with Dicer knockdown in 
osteoclast precursors and mature osteoclasts [78]. 
Expres  sion of a CD11b promoter driven-Cre transgene in 
mice bearing ﬂ  oxed Dicer alleles resulted in increased 
trabecular bone volume. Th   e mice had decreased 
Table 1. Summary of microRNAs, their targets, expression, and eff  ects on osteoblast diff  erentiation
miRNA
Target 
gene(s)
Endogenous miRNA 
expression miRNA over-expression miRNA inhibition Reference
125b NR Decreased in BMP4-induced 
osteoblastic diff  erentiation of ST2 
cells 
Inhibits ALP activity Increases ALP activity [58]
133 Runx2 Decreased in BMP2-induced 
osteoblast diff  erentiation of C2C12 
cells
Decreases ALP and osteocalcin 
mRNA
NR [49]
135 Smad5
141, 
200a
Dlx5 Repressed by BMP in MC3T3-E1 
cells
Inhibits ALP activity Increases ALP activity [54]
199a, 
346
LIF Increased during osteoblast 
diff  erentiation of hMSCs
NR NR [46]
204 Runx2 Increased in C3H10T1/2 cells and 
hMSCs during adipogenesis
Enhances adipogenesis (increases 
oil red O staining, and AP2, 
adipsin, and PPARγ mRNA); inhibits 
osteoblastogenesis (decreases ALP 
activity, and ALP, osteopontin, and 
osteocalcin mRNA)
Enhances osteoblastogenesis 
(increases ALP activity, and ALP, 
osteopontin, and osteocalcin 
mRNA); inhibits adipogenesis 
(decreases oil red O staining, and 
AP2, adipsin, and PPARγ mRNA)
[61]
206 Connexin 43 Decreased in BMP2-induced 
osteoblastic diff  erentiation of 
C2C12 cells; deceased during 
osteoblastic diff  erentiation of 
primary mouse osteoblasts
Causes osteopenia in vivo; decreases 
osteocalcin and Runx2 mRNA, and 
ALP activity; increases myogenic 
markers (MyoD, Myf5)
Increases ALP activity [52]
208 Ets1 Repressed by BMP treatment in 
MC3T3-E1 cells
Decreases ALP activity, Alizarin red 
staining, and osteopontin protein
No eff  ect [56]
210 AcvR1b Increased in BMP4-induced 
osteoblastic diff  erentiation of ST2 
cells
Increases ALP, osteocalcin, and 
osterix mRNA, and ALP activity
Decreases osteocalcin mRNA  [59]
23a/27a/
24-2
Runx2, SATB2 Increased during osteoblastic 
diff  erentiation of rat primary 
osteoblasts
Decreases ALP activity and mRNA, 
vonKossa staining, Runx2, osterix, 
and osteocalcin mRNA
NR [62]
26a SMAD1 Increased during terminal 
osteoblastic diff  erentiation in 
hADSCs
NR Increases ALP, osteopontin, and 
osteocalcin mRNA
[63]
27 APC Increased during osteoblastic 
diff  erentiation of hFOB 1.19 cells
Increases ALP and osteocalcin 
mRNA; augments Wnt signaling
Decreases ALP and osteocalcin 
mRNA
[73]
2861 HDAC5 Increased in BMP2-induced 
osteoblastic diff  erentiation of ST2 
cells; enriched in human bone
Augments BMP-induced increase in 
osteocalcin mRNA
Decreases bone volume and BFR 
in vivo; patients homozygous for 
miR-2861 mutation have very low 
bone mass
[74]
29a, 
29c
COL1A1, COL3A1, 
Osteonectin/ 
SPARC, Kremen2, 
Dkk1, Sfrp2
Increased during osteoblastic 
diff  erentiation in MC3T3-E1 cells, 
primary osteoblasts (human and 
mouse), and hFOB1.19 cells
Increases osteocalcin mRNA; 
potentiates Wnt signaling 
Inhibits ALP and osteocalcin 
mRNA, and ALP activity; blunts Wnt 
signaling
[60,68,
72]
29b COL1A1, HDAC4, 
DUSP2, TGFβ3, 
AcvR2a, CTNNBIP1
Increased during osteoblastic 
diff  erentiation in MC3T3-E1 cells
Increases ALP mRNA and ALP activity NR [70]
3960 Hoxa2 Increased in response to BMP-2 in 
mouse primary osteoblasts
Increases ALP, osteocalcin, and Runx2 
mRNA
Decreases ALP, osteocalcin, and 
Runx2 mRNA
[76]
ALP, alkaline phosphatase; BFR, bone formation rate; BMP, bone morphogenetic protein; hADSC, human adipocyte derived stem cell; hMSC, human mesenchymal 
stem cell; miRNA, microRNA; NR, not reported; PPAR, peroxisome proliferator-activated receptor.
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Page 8 of 11osteo  clast numbers and decreased bone resorption, 
without alterations in osteoblast parameters. In vitro, 
small interfering RNA-mediated knockdown 
(approximately 60% knockdown) of DGCR8, Ago2, or 
Dicer1 in mouse BMMs antagonized the RANKL-
induced stimulation of osteoclast diﬀ  erentiation markers, 
including c-fos, PU.1, and NFATc1 [78].
Th  is group also studied the function of miR-223 in 
osteoclastogenesis, since it is expressed in osteoclast 
precursors. Knockdown of miR-223 decreased the 
RANKL-induced formation of osteoclast-like cells in 
mouse RAW264.7 cells. However, over-expression of 
miR-223 also had a similar eﬀ  ect. Th   ese data suggest that 
appropriate levels of miR-223 expression are important 
for normal osteoclastogenesis. Interestingly, knockdown 
of miR-223 resulted in an increase in NFI-A, a suppressor 
of osteoclastogenesis. Bioinformatics suggests that the 3’ 
UTR for NFI-A may have a potential miR-223 binding 
site. Further, two PU.1 binding sites are present in the 
miR-223 promoter region [79]. Th   e authors hypothesize 
that in osteoclast precursors, PU.1, induced by MCSF, 
may stimulate transcription of miR-223 and RANK. 
Mature miR-223 then likely targets NFI-A to increase 
expression of MCSF receptor, which is critical for 
osteoclast diﬀ  erentiation, function, and survival [80].
Another group demonstrated increased association of c-
Fos and PU.1 with the miR-21 promoter during osteo  clast 
diﬀ  erentiation of mouse BMMs [81]. In BMMs transduced 
with a miR-21-antisense lentivirus, expres  sion of PDCD4 
(programmed cell death 4), a repressor of c-Fos, was 
increased. Th  is  eﬀ  ect correlated with decreased osteoclast 
diﬀ   erentiation markers, including c-Fos, cathepsin K, 
NFATc1, and TRAP staining, compared to controls.
In contra    st, miR-155 acts as a molecular switch in 
monocytic cells to repress osteoclast formation and pro-
mote the macrophage fate [82]. miR-155 is down-
regulated in osteoclasts and up-regulated in macro-
phages. Over-expression of miR-155 in RAW 264.7 
mono  cytes blocked the formation of multinucleated 
osteo  clasts, suppressed TRAP staining, blocked bone-
resorb  ing activity, and increased macrophage diﬀ  eren-
tiation. Conversely, knockdown of miR-155 caused an 
increase in osteoclasts and decrease in macrophages. Th  e 
authors found that microphthalmia-associated trans-
cription factor is a direct target of miR-155, and that it 
activates transcription of GPNMB (glycoprotein NMB, 
osteoactivin), a transmembrane protein critical for 
osteoclast diﬀ  erentiation. Th  erefore, down-regulation of 
miR-155 is important for osteoclastogenesis.
As with osteoblasts, there is likely a panel of miRNAs 
important for osteoclast function and diﬀ  erentiation. 
More research will reveal these miRNAs and how they 
interact with signaling molecules to control osteoclast 
phenotypes.
Conclusion
Th  ese studies represent the ﬁ  rst steps in demonstrating 
the importance of miRNAs in the control of osteoblast 
and osteoclast diﬀ  erentiation and function, and their role 
in bone turnover. An in-depth understanding of the roles 
of these regulatory RNAs in the skeleton will be critical 
for the development of new therapeutics aimed at 
treating bone loss and perhaps facilitating fracture repair. 
Although current therapies can be eﬀ  ective at preventing 
bone loss, there are patients who are refractory to 
treatment. Th  e inhibition or over-expression of certain 
miRNAs in a tissue-speciﬁ   c manner has shown some 
promise in the treatment of tumors in animal models, 
and miRNA-based therapeutics have recently gone into 
clinical trials [83]. Th  ere are two obvious beneﬁ  ts  of 
miRNA-based therapeutics. miRNA oligonucleotide 
inhibitors or mimics can be targeted to speciﬁ  c tissues 
using relatively non-toxic delivery vehicles. In addition, 
these molecules can be relatively cost-eﬀ  ective compared 
to current peptide-based therapies. Much more work 
needs to be done to determine which miRNAs are 
important in bone, and to deﬁ   ne their roles in bone 
remodeling, fracture repair, and bone-related diseases.
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